| Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood MAL Eissa, L Lerner, E Abdelfatah, N Shankar, JK Canner, NM Hasan, ... Clinical epigenetics 11, 1-10, 2019 | 142 | 2019 |
| Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer ES Reisenbichler, G Han, A Bellizzi, V Bossuyt, J Brock, K Cole, O Fadare, ... Modern pathology 33 (9), 1746-1752, 2020 | 112 | 2020 |
| Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer M Moutafi, CJ Robbins, V Yaghoobi, AI Fernandez, S Martinez-Morilla, ... Laboratory Investigation 102 (10), 1101-1108, 2022 | 67 | 2022 |
| Antibody validation for protein expression on tissue slides: a protocol for immunohistochemistry T MacNeil, IA Vathiotis, S Martinez-Morilla, V Yaghoobi, J Zugazagoitia, ... Biotechniques 69 (6), 460-468, 2020 | 40 | 2020 |
| Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas J Yeung, V Yaghoobi, D Miyagishima, MD Vesely, T Zhang, T Badri, ... Neuro-oncology 23 (11), 1922-1935, 2021 | 39 | 2021 |
| Immunological differences between immune-rich estrogen receptor–positive and immune-rich triple-negative breast cancers T O’Meara, M Marczyk, T Qing, V Yaghoobi, K Blenman, K Cole, ... JCO Precision Oncology 3, 767-779, 2020 | 38 | 2020 |
| Predictive markers of response to neoadjuvant durvalumab with nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in basal-like triple-negative breast cancer KRM Blenman, M Marczyk, T Karn, T Qing, X Li, V Gunasekharan, ... Clinical Cancer Research 28 (12), 2587-2597, 2022 | 22 | 2022 |
| Discovery of biomarkers of resistance to immune checkpoint blockade in NSCLC using high-plex digital spatial profiling M Moutafi, S Martinez-Morilla, P Divakar, I Vathiotis, N Gavrielatou, ... Journal of Thoracic Oncology 17 (8), 991-1001, 2022 | 21 | 2022 |
| Alpha-smooth muscle actin expression in the stroma predicts resistance to trastuzumab in patients with early-stage HER2-positive breast cancer IA Vathiotis, MK Moutafi, P Divakar, TN Aung, T Qing, A Fernandez, ... Clinical Cancer Research 27 (22), 6156-6163, 2021 | 18 | 2021 |
| Advances in quantitative immunohistochemistry and their contribution to breast cancer V Yaghoobi, S Martinez-Morilla, Y Liu, L Charette, DL Rimm, M Harigopal Expert Review of Molecular Diagnostics 20 (5), 509-522, 2020 | 17 | 2020 |
| Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithms TN Aung, S Shafi, JS Wilmott, S Nourmohammadi, I Vathiotis, ... EBioMedicine 82, 2022 | 16 | 2022 |
| Spatially resolved and quantitative analysis of the immunological landscape in human meningiomas J Yeung, V Yaghoobi, TN Aung, MD Vesely, T Zhang, P Gaule, M Gunel, ... Journal of Neuropathology & Experimental Neurology 80 (2), 150-159, 2021 | 11 | 2021 |
| Programmed death-ligand 1 and programmed death-ligand 2 mRNAs measured using closed-system quantitative real-time polymerase chain reaction are associated with outcome and high … AI Fernandez, N Gavrielatou, L McCann, S Shafi, MK Moutafi, ... Journal of Thoracic Oncology 17 (9), 1078-1085, 2022 | 10 | 2022 |
| Development of an immunohistochemical assay for Siglec-15 S Shafi, TN Aung, C Robbins, J Zugazagoitia, I Vathiotis, N Gavrielatou, ... Laboratory Investigation 102 (7), 771-778, 2022 | 10 | 2022 |
| Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer S Shafi, TN Aung, V Xirou, N Gavrielatou, IA Vathiotis, A Fernandez, ... Laboratory Investigation 102 (10), 1143-1149, 2022 | 9 | 2022 |
| Suppression of dsRNA response genes and innate immunity following Oct4, Stella, and Nanos2 overexpression in mouse embryonic fibroblasts M Farshchian, MM Matin, O Armant, D Geerts, M Dastpak, S Nakhaei-Rad, ... Cytokine 106, 1-11, 2018 | 7 | 2018 |
| Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case–control study V Yaghoobi, M Moutafi, TN Aung, V Pelekanou, S Yaghoubi, K Blenman, ... Breast Cancer Research 23, 1-12, 2021 | 6 | 2021 |
| Phase II window study of olaparib alone or with cisplatin or durvalumab in operable head and neck cancer M Moutafi, GA Koliou, G Papaxoinis, P Economopoulou, I Kotsantis, ... Cancer Research Communications 3 (8), 1514-1523, 2023 | 4 | 2023 |
| Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays in triple negative breast cancer ES Reisenbichler, G Han, V Pelekanou, V Yaghoobi, FS Ahmed, ... CANCER RESEARCH 80 (4), 2020 | 4 | 2020 |
| Abstract P3-09-05: Predictive markers of response to durvalumab concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) neoadjuvant therapy for triple … KRM Blenman, X Li, M Marczyk, T O'Meara, V Yaghoobi, V Gunasekharan, ... Cancer Research 80 (4_Supplement), P3-09-05-P3-09-05, 2020 | 2 | 2020 |
